endeavor, and now nanomedicines are going to be understood in detail so as to
enable the investigators predict easily the fate, success of targeted delivery and side
effect.
Tracer kinetic analysis is now well established in nuclear medicine and individualized dosimetry upon this kinetic understanding is underway. Every new small
molecular radiopharmaceutical or biologics used to go through the elucidation
procedures of biodistribution and radiation absorbed dose distribution and expected
administered radiation to the target of interest. Nuclear medicine can easily adopt
the nanomaterials and do the same way to reveal the possible advantage of using
nanomaterials instead of biologics. It is an easy expansion of the discipline’s
principle, nevertheless the exploration of new opportunity. Nuclear medicine will
discard immediately the radionanomedicines if the adopted nanomaterials are toxic
or do not behave as we expected or too cumbersome to handle. Compounding
radiopharmaceutical with radionuclides at bedside is a common practice in nuclear
medicine and even the production of the nanomedicines and compounding procedure using radionuclides at bedside are prolonged, then again nuclear medicine will
not adopt the radionanomedicines.
As time goes by, chemistry and chemical engineering come to be more and more
versatile to fabricate nanomedicines in good manufacturing practice (GMP) and
supply radionanomedicine precursors to the clinic, and then nuclear medicine
physicians will be glad to use them after an easy labeling for theranostic, therapeutic or diagnostic imaging purpose. Individual radiation dosimetry and determination of the appropriate dose to the patients and optimal time schedules are
going to be devised soon. That is the way how radionanomedicine shall enter the
clinical arena. Clinical radionanomedicine is the next discipline when several
successful radionanomedicines are approved and compounding procedures come to
be popular in clinical practice. Platform technology is to be developed for realization of this expected clinical future.
Radionanomedicine is the ultimate future of nanomedicine. Nanomedicines are
not going to be adopted easily in clinical medicine with so many unknowns.
Radionanomedicines, if successfully meet the criteria of approval for biologics, will
soon appear at the clinic, and nuclear medicine physicians are going to accommodate the procedures and get very much familiar in using them, then again
nanomedicines might come back on their own to become independent drugs for
clinical use. The trap of lack of knowledge will be overcome by radionanomedicine.
We need to take efforts to make things practical and understand the details and
always vigilant for the possible human and clinical use of these huge pools of
materials that humankind never encountered in their long history of evolution.
With the themes passionately explained above, keeping in mind the advantage or
beauty of radionanomedicine, I edited this book as follows. This was extended
endeavor I and my colleagues published the first review article in 2015 in
Nanomedicine, nanotechnology, biology and medicine [1]. After that, the concept
was refined again and again in many presentations at global congresses and conferences of either nuclear medicine society or nanomedicine society. Systematic
description of the problems which have been solved and more problems which need
4
D. S. Lee
enable the investigators predict easily the fate, success of targeted delivery and side
effect.
Tracer kinetic analysis is now well established in nuclear medicine and individualized dosimetry upon this kinetic understanding is underway. Every new small
molecular radiopharmaceutical or biologics used to go through the elucidation
procedures of biodistribution and radiation absorbed dose distribution and expected
administered radiation to the target of interest. Nuclear medicine can easily adopt
the nanomaterials and do the same way to reveal the possible advantage of using
nanomaterials instead of biologics. It is an easy expansion of the discipline’s
principle, nevertheless the exploration of new opportunity. Nuclear medicine will
discard immediately the radionanomedicines if the adopted nanomaterials are toxic
or do not behave as we expected or too cumbersome to handle. Compounding
radiopharmaceutical with radionuclides at bedside is a common practice in nuclear
medicine and even the production of the nanomedicines and compounding procedure using radionuclides at bedside are prolonged, then again nuclear medicine will
not adopt the radionanomedicines.
As time goes by, chemistry and chemical engineering come to be more and more
versatile to fabricate nanomedicines in good manufacturing practice (GMP) and
supply radionanomedicine precursors to the clinic, and then nuclear medicine
physicians will be glad to use them after an easy labeling for theranostic, therapeutic or diagnostic imaging purpose. Individual radiation dosimetry and determination of the appropriate dose to the patients and optimal time schedules are
going to be devised soon. That is the way how radionanomedicine shall enter the
clinical arena. Clinical radionanomedicine is the next discipline when several
successful radionanomedicines are approved and compounding procedures come to
be popular in clinical practice. Platform technology is to be developed for realization of this expected clinical future.
Radionanomedicine is the ultimate future of nanomedicine. Nanomedicines are
not going to be adopted easily in clinical medicine with so many unknowns.
Radionanomedicines, if successfully meet the criteria of approval for biologics, will
soon appear at the clinic, and nuclear medicine physicians are going to accommodate the procedures and get very much familiar in using them, then again
nanomedicines might come back on their own to become independent drugs for
clinical use. The trap of lack of knowledge will be overcome by radionanomedicine.
We need to take efforts to make things practical and understand the details and
always vigilant for the possible human and clinical use of these huge pools of
materials that humankind never encountered in their long history of evolution.
With the themes passionately explained above, keeping in mind the advantage or
beauty of radionanomedicine, I edited this book as follows. This was extended
endeavor I and my colleagues published the first review article in 2015 in
Nanomedicine, nanotechnology, biology and medicine [1]. After that, the concept
was refined again and again in many presentations at global congresses and conferences of either nuclear medicine society or nanomedicine society. Systematic
description of the problems which have been solved and more problems which need
4
D. S. Lee